Literature DB >> 20145164

Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies.

Gerhardt Attard, Johann S de Bono, Jeremy Clark, Colin S Cooper.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20145164      PMCID: PMC3513707          DOI: 10.1158/1078-0432.CCR-09-2253

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion.

Authors:  Charles C Guo; Geyan Zuo; Dongdong Cao; Patricia Troncoso; Bogdan A Czerniak
Journal:  Mod Pathol       Date:  2009-04-24       Impact factor: 7.842

Review 2.  ETS gene fusions in prostate cancer.

Authors:  Jeremy P Clark; Colin S Cooper
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

3.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.

Authors:  Juan-Miguel Mosquera; Rohit Mehra; Meredith M Regan; Sven Perner; Elizabeth M Genega; Gerri Bueti; Rajal B Shah; Sandra Gaston; Scott A Tomlins; John T Wei; Michael C Kearney; Laura A Johnson; Jeffrey M Tang; Arul M Chinnaiyan; Mark A Rubin; Martin G Sanda
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

4.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Authors:  Gerhardt Attard; Joost F Swennenhuis; David Olmos; Alison H M Reid; Elaine Vickers; Roger A'Hern; Rianne Levink; Frank Coumans; Joana Moreira; Ruth Riisnaes; Nikhil Babu Oommen; George Hawche; Charles Jameson; Emilda Thompson; Ronald Sipkema; Craig P Carden; Christopher Parker; David Dearnaley; Stan B Kaye; Colin S Cooper; Arturo Molina; Michael E Cox; Leon W M M Terstappen; Johann S de Bono
Journal:  Cancer Res       Date:  2009-04-01       Impact factor: 12.701

5.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.

Authors:  G Attard; J Clark; L Ambroisine; G Fisher; G Kovacs; P Flohr; D Berney; C S Foster; A Fletcher; W L Gerald; H Moller; V Reuter; J S De Bono; P Scardino; J Cuzick; C S Cooper
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

  5 in total
  8 in total

Review 1.  Genomic rearrangements in prostate cancer.

Authors:  Christopher E Barbieri; Mark A Rubin
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

Review 2.  The mutational landscape of prostate cancer.

Authors:  Christopher E Barbieri; Chris H Bangma; Anders Bjartell; James W F Catto; Zoran Culig; Henrik Grönberg; Jun Luo; Tapio Visakorpi; Mark A Rubin
Journal:  Eur Urol       Date:  2013-05-18       Impact factor: 20.096

3.  TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.

Authors:  Daniel C Danila; Aseem Anand; Clifford C Sung; Glenn Heller; Margaret A Leversha; Long Cao; Hans Lilja; Arturo Molina; Charles L Sawyers; Martin Fleisher; Howard I Scher
Journal:  Eur Urol       Date:  2011-07-14       Impact factor: 20.096

4.  ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.

Authors:  K-C Huang; M Dolph; B Donnelly; T A Bismar
Journal:  Clin Transl Oncol       Date:  2014-05-06       Impact factor: 3.405

Review 5.  The complexity of prostate cancer: genomic alterations and heterogeneity.

Authors:  Lara K Boyd; Xueying Mao; Yong-Jie Lu
Journal:  Nat Rev Urol       Date:  2012-11       Impact factor: 14.432

6.  Oncogenic activation of ERG: A predominant mechanism in prostate cancer.

Authors:  Taduru L Sreenath; Albert Dobi; Gyorgy Petrovics; Shiv Srivastava
Journal:  J Carcinog       Date:  2011-12-31

7.  ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer.

Authors:  Liang Hong Teng; Cheng Wang; Michael Dolph; Bryan Donnelly; Tarek A Bismar
Journal:  ISRN Urol       Date:  2013-08-19

Review 8.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.

Authors:  R Ferraldeschi; J Welti; J Luo; G Attard; J S de Bono
Journal:  Oncogene       Date:  2014-05-19       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.